Radionenhancer | Nano Publications

2020 – SITC – NBTXR3 Generates Long Term Immune Memory

Congress Abstracts, In Vitro in Vivo NBTXR3, In Vivo

Although treatment of high-dose (HD) radiation (XRT) and NBTXR3 (R3) on primary tumors in combination with systemic anti-PD1 was able to significantly improve abscopal effect in 344SQR murine metastatic lung cancer, most of the mice eventually expired due to the growth of metastatic tumors. Therefore, we studied the effects of R3 injection into primary tumors plus high-dose radiation on primary tumor and low-dose raditionon metastatic tumor plus dual-agent immunotherapy (IT) of anti-PD1 and anti-CTLA-4 to achive complete control of tumor growth at both the primary and the metastatic tumors in mice. […]

2017 – Immunotherapy Workshop

Congress Abstracts, In Vitro in Vivo NBTXR3, In Vivo

Radiotherapy (RT) has proven its ability to function like an in-situ vaccine, showing potential for successful combination with immunotherapeutic agents. Hafnium oxide nanoparticle (HfO2-NP), undergoing clinical trials for enhancing RT, was designed as high electron density material at the nanoscale. HfO2-NPs are taken up by cancer cells and, when exposed to RT, locally increase the radiation dose deposit, triggering more cancer cells death when compared to RT. We hypothesized that HfO2-NP+RT could trigger an enhanced immune response when compared to RT, both in preclinical and clinical settings.

2017 – AACR Abstract – NBTXR3 combination with cisplatin in vivo and in vitro

Congress Abstracts, In Vitro, In Vitro in Vivo NBTXR3, In Vivo

Combination of NBTXR3 and cisplatin has been evaluated in vitro and in vivo. No specific toxicity was observed for the cells exposed only to NBTXR3. For the combined treatment, a marked and enhanced cell destruction when compared to the single agent. In vivo, NBTXR3 combined with low dose of cisplatin delayed tumor growth when compared to single agent CDDP in combination with RT. NBTXR3 is intended to be injected in the tumors. Spilling in the circulation may occur during product administration or, as expected, during tumor destruction, leading to steady trapping of NPs in the reticulo-endothelial system (liver and spleen). Clinically, it is unknown whether patients, previously treated with NPs, may show toxic signs when NPs are exposed (activation) to diagnosis imaging (computed tomography(CT)) of the liver.

2015 – Metals as radio-enhancers in oncology – Pottier et al.

Miscellaneous, NO-RIGHTS, Publications

Radio-enhancers, metal-based nanosized agents, could play a key role in oncology. They may unlock the potential of radiotherapy by enhancing the radiation dose deposit within tumors when the ionizing radiation source is ‘on’, while exhibiting chemically inert behavior in cellular and subcellular systems when the radiation beam is ‘off’. Important decision points support the development of these new type of therapeutic agents originated from nanotechnology. Here, we discuss from an industry perspective, the interest of developing radio-enhancer agents to improve tumor control, the relevance of nanotechnology to achieve adequate therapeutic attributes, and present some considerations for their development in oncology.

2014 – NBTXR3 concept and dose enhancement – Marill et al.

In Vitro, In Vitro in Vivo NBTXR3, NO-RIGHTS, Publications

Hafnium oxide, NBTXR3 nanoparticles were designed for high dose energy deposition within cancer cells when exposed to ionizing radiation. The purpose of this study was to assess the possibility of predicting the in vitro the biological effect of NBTXR3 nanoparticles when exposed to ionizing radiation. Cellular uptake of NBTXR3 nanoparticles was assessed in a panel of human cancer cell lines (radioresistant and radiosensitive) by transmission electron microscopy. The radioenhancement of NBTXR3 nanoparticles was measured by the clonogenic survival assay.